Description

IDRA-21 Powder

IDRA-21
CAS Number	22503-72-6
Molar Mass	232.68 g·mol−1
Chemical Formula	C8H9ClN2O2S
IUPAC Name	7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide

Introduction

IDRA-21 Powder represents an exclusive research product explicitly designed for scientific inquiry, devoid of any association with human consumption. This powdered formulation of IDRA-21 serves as a tool for researchers to delve into its unique properties and potential benefits in the realms of memory, focus, and overall cognition.

Key Characteristics

IDRA-21, a member of the ampakine class, possesses distinct pharmacological characteristics that set it apart. Recognized for its modulatory effects on glutamate receptors, IDRA-21 has drawn attention to its potential impact on synaptic plasticity and cognitive function.

Research Applications

IDRA-21 Powder finds versatile applications in research domains, providing researchers with a valuable tool to investigate its potential benefits, with a specific focus on memory, focus, and overall cognition.

Research Benefits

IDRA-21 and Memory and Focus

Studies suggest that IDRA-21 may have a positive impact on memory and focus by modulating glutamate receptors, potentially enhancing synaptic plasticity. Research in this domain aims to elucidate its potential applications in addressing conditions related to cognitive performance.

IDRA-21 and Overall Cognition

Preliminary research indicates that IDRA-21 may influence overall cognition through its effects on glutamate receptors. Investigations into its impact on cognitive processes contribute to our understanding of its potential applications in cognitive enhancement research (Reference 2).

Summary

IDRA-21 Powder, crafted exclusively for research purposes, provides researchers with a unique avenue for investigating the potential benefits of IDRA-21 in memory, focus, and overall cognition. The distinctive characteristics of IDRA-21 make it a promising subject for further exploration in neuroscientific and cognitive research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Thompson DM, Guidotti A, DiBella M, Costa E. 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S, S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7667-71. doi: 10.1073/pnas.92.17.7667. PMID: 7644474; PMCID: PMC41206. [Read More].
2. Purves D, Augustine GJ, Fitzpatrick D, et al., editors. Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates; 2001. Long-Term Synaptic Potentiation. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10878/ [Read More].